These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 1560191)
1. Remission of Raynaud's phenomenon after L-thyroxine therapy in a patient with hypothyroidism. Lateiwish AM; Fehér J; Baraczka K; Rácz K; Kiss R; Gláz E J Endocrinol Invest; 1992 Jan; 15(1):49-51. PubMed ID: 1560191 [TBL] [Abstract][Full Text] [Related]
8. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma. Colakoğlu M; Cobankara V; Akpolat T Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574 [TBL] [Abstract][Full Text] [Related]
9. Multidisciplinary Treatment for Severe Secondary Raynaud's Phenomenon: A Case Report. Leng CB; Lin GJ; Cao H; Liu ZJ Chin Med Sci J; 2022 Dec; 37(4):353-358. PubMed ID: 36316060 [TBL] [Abstract][Full Text] [Related]
10. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis]. Serri J; Legré R; Veit V; Guardia C; Gay AM Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894 [TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin type A in the treatment of Raynaud's phenomenon. Habib SM; Brenninkmeijer EEA; Vermeer MH; de Vries-Bouwstra JK; Velthuis PJ Dermatol Ther; 2020 Nov; 33(6):e14182. PubMed ID: 32794364 [TBL] [Abstract][Full Text] [Related]
12. [Validity of plethysmography and the digital temperature recovery test in the diagnosis of primary and occupational Raynaud's phenomenon]. Laroche GP; Thériault G Clin Invest Med; 1987 Mar; 10(2):96-102. PubMed ID: 3581549 [TBL] [Abstract][Full Text] [Related]
13. The diagnosis and treatment of Raynaud's phenomenon. Porter JM; Snider RL; Bardana EJ; Rösch J; Eidemiller LR Surgery; 1975 Jan; 77(1):11-23. PubMed ID: 1078555 [TBL] [Abstract][Full Text] [Related]
14. Warfarin-associated multiple digital necrosis complicating heparin-induced thrombocytopenia and Raynaud's phenomenon after aortic valve replacement for adenocarcinoma-associated thrombotic endocarditis. Warkentin TE; Whitlock RP; Teoh KH Am J Hematol; 2004 Jan; 75(1):56-62. PubMed ID: 14695634 [TBL] [Abstract][Full Text] [Related]
15. Clinical and image improvement of Raynaud's phenomenon after botulinum toxin type A treatment. Zhao H; Lian Y Australas J Dermatol; 2015 Aug; 56(3):202-5. PubMed ID: 25817568 [TBL] [Abstract][Full Text] [Related]
16. Isosorbide dinitrate ointment in Raynaud's disease. Diehm C; Müller-Bühl U; Mörl H Z Kardiol; 1983; 72 Suppl 3():185-7. PubMed ID: 6364591 [TBL] [Abstract][Full Text] [Related]
17. Reproducibility of cold provocation in patients with Raynaud's phenomenon. Wigley FM; Malamet R; Wise RA J Rheumatol; 1987 Aug; 14(4):751-5. PubMed ID: 3668980 [TBL] [Abstract][Full Text] [Related]
18. [The therapy of Raynaud's phenomenon]. Di Giacinto G Clin Ter; 1993 Feb; 142(2):161-74. PubMed ID: 8472530 [TBL] [Abstract][Full Text] [Related]
19. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Fries R; Shariat K; von Wilmowsky H; Böhm M Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885 [TBL] [Abstract][Full Text] [Related]